低HER2和HER2-零乳腺癌患者的预后差异:系统性审查和元分析
Chengxin Li1, Qianqian Yuan1, Tong Deng1
1Department of Thyroid and Breast Surgery, Zhongnan Hospital Wuhan University, Wuhan, China.
Breast cancer (Tokyo, Japan)
|July 20, 2023
概括
与HER2-零患者相比,HER2-低乳腺癌患者的整体存活率和无病存活率有所改善. 这一发现适用于不同的激素受体状态,这表明HER2-低乳腺癌的明显预后价值.
科学领域:
- 在瘤学瘤学.
- 遗传学 遗传学 是一个
- 生物标志物 生物标志物
背景情况:
- 低HER2乳腺癌 (BC) 通过特定免疫组织化学 (IHC) 评分 (1+或2+) 和非放大局部杂交 (ISH) 结果来定义.
- 在医学界,HER2-低BC的预后意义仍在争论中.
- 这一元分析研究了HER2-低和HER2-零乳腺癌特征之间的预后差异.
结论:
- 与HER2-零患者相比,HER2-低乳腺癌患者表现出更高的OS和DFS.
- 低HER2状态的预后值在各种HR状态中是一致的.
- 需要进一步的研究来阐明独立亚型的地位,并充分描述HER2-低乳腺癌的分子和临床特征.
更多相关视频
相关概念视频
Cancer Survival Analysis
390
Cancer survival analysis focuses on quantifying and interpreting the time from a key starting point, such as diagnosis or the initiation of treatment, to a specific endpoint, such as remission or death. This analysis provides critical insights into treatment effectiveness and factors that influence patient outcomes, helping to shape clinical decisions and guide prognostic evaluations. A cornerstone of oncology research, survival analysis tackles the challenges of skewed, non-normally...
390
Comparing the Survival Analysis of Two or More Groups
226
Survival analysis is a cornerstone of medical research, used to evaluate the time until an event of interest occurs, such as death, disease recurrence, or recovery. Unlike standard statistical methods, survival analysis is particularly adept at handling censored data—instances where the event has not occurred for some participants by the end of the study or remains unobserved. To address these unique challenges, specialized techniques like the Kaplan-Meier estimator, log-rank test, and...
226


